Table of Contents
Thrombosis
Volume 2014, Article ID 649652, 5 pages
http://dx.doi.org/10.1155/2014/649652
Research Article

Elevated Heparin-Induced Antibodies Are More Common in Diabetic Patients with Vascular Disease

1Lebanese American University and University Medical Center Rizk Hospital, P.O. Box 11-3288, Zahar Street, Achrafieh, Beirut, Lebanon
2Houston Methodist and DeBakey Heart and Vascular Center, Houston, TX, USA

Received 31 October 2013; Accepted 30 December 2013; Published 6 February 2014

Academic Editor: Louis M. Aledort

Copyright © 2014 Joseph J. Naoum et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Kroegel and A. Reissig, “Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis,” Respiration, vol. 70, no. 1, pp. 7–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. A. T. Hirsch, Z. J. Haskal, N. R. Hertzer et al., “ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation,” Circulation, vol. 113, no. 11, pp. e463–e654, 2006. View at Google Scholar
  3. A. Hughes, B. A. McVerry, and L. Wilkinson, “Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients,” Acta Haematologica, vol. 69, no. 4, pp. 254–259, 1983. View at Google Scholar · View at Scopus
  4. S. P. Jackson and H. H. Salem, “Platelet aggregating activity in the plasma of patients with established thrombosis,” Australian and New Zealand Journal of Medicine, vol. 19, no. 2, pp. 126–131, 1989. View at Google Scholar · View at Scopus
  5. M. E. Carr, “Diabetes mellitus: a hypercoagulable state,” Journal of Diabetes and its Complications, vol. 15, no. 1, pp. 44–54, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. J. G. Kelton, “The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment,” Chest, vol. 127, no. 2, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Blank, Y. Shoenfeld, S. Tavor et al., “Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells,” International Immunology, vol. 14, no. 2, pp. 121–129, 2002. View at Google Scholar · View at Scopus
  8. J. Diaz, M. Prechel, M. Emanuele, N. Emanuele, and J. M. Walenga, “Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes,” Clinical and Applied Thrombosis/Hemostasis, vol. 16, no. 2, pp. 121–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Sarkar, A. Assadian, H. Frank, G. Moessmer, U. Heemann, and H.-H. Eckstein, “Hereditary and acquired thrombophilic disorders complicating vascular access in haemodialysis,” NDT Plus, vol. 3, no. 4, pp. 393–396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Bennett-Guerrero, T. F. Slaughter, W. D. White et al., “Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery,” Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 6, pp. 1567–1572, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. G. M. Arepally and M. J. Hursting, “Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results,” Journal of Thrombosis and Thrombolysis, vol. 26, no. 1, pp. 55–61, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. V. Mattioli, L. Bonetti, S. Sternieri, and G. Mattioli, “Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up,” Italian Heart Journal, vol. 1, no. 1, pp. 39–42, 2000. View at Google Scholar · View at Scopus
  13. W. K. Stribling, T. F. Slaughter, T. T. Houle, and D. C. Sane, “Beyond the platelet count: heparin antibodies as independent risk predictors,” American Heart Journal, vol. 153, no. 6, pp. 900–906, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. V. Mattioli, L. Bonetti, U. Carletti, G. Ambrosio, and G. Mattioli, “Thrombotic events in patients with antiplatelet factor 4/heparin antibodies,” Heart, vol. 95, no. 16, pp. 1350–1354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Krane, M. Berger, J. Lilienthal, K. Winkler, C. Schambeck, and C. Wanner, “Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 874–881, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Zhao, X. Sun, L. Yao et al., “The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up,” PLoS ONE, vol. 8, no. 4, Article ID e62239, 2013. View at Google Scholar
  17. D. Q. Borsey, C. V. Prowse, and R. S. Gray, “Platelet and coagulation factors in proliferative diabetic retinopathy,” Journal of Clinical Pathology, vol. 37, no. 6, pp. 659–664, 1984. View at Publisher · View at Google Scholar · View at Scopus
  18. M. S. Roy, M. J. Podgor, and M. E. Rick, “Plasma fibrinopeptide A, β-thromboglobulin, and platelet factor 4 in diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 29, no. 6, pp. 856–860, 1988. View at Google Scholar · View at Scopus
  19. M. M. Prechel and J. M. Walenga, “Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocytopenia,” Thrombosis Journal, vol. 11, no. 1, p. 7, 2013. View at Google Scholar
  20. E. J. Dunn and P. J. Grant, “Type 2 diabetes: an atherothrombotic syndrome,” Current Molecular Medicine, vol. 5, no. 3, pp. 323–332, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. G. Tilton, “Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF,” Microscopy Research and Technique, vol. 57, no. 5, pp. 390–407, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Nadlinger, J. Birkmayer, F. Gebauer, and R. Kunze, “Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes,” NeuroImmunoModulation, vol. 9, no. 4, pp. 203–208, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Cacciapuoti, “Some considerations about the hypercoagulable states and their treatments,” Blood Coagulation and Fibrinolysis, vol. 22, no. 3, pp. 155–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. L. Adams, E. W. Paxton, J. Q. Wang et al., “Surgical outcomes of total knee replacement according to diabetes status and glycemic control, 2001 to 2009,” Journal of Bone and Joint Surgery. American, vol. 95, no. 6, pp. 481–487, 2013. View at Google Scholar
  25. S. Wang and Y. Zhao, “Diabetes mellitus and the incidence of deep vein thrombosis after total knee arthroplasty: a retrospective study,” The Journal of Arthroplasty, vol. 28, no. 4, pp. 595–597, 2013. View at Google Scholar
  26. G. Piazza, S. Z. Goldhaber, A. Kroll, R. J. Goldberg, C. Emery, and F. A. Spencer, “Venous thromboembolism in patients with diabetes mellitus,” American Journal of Medicine, vol. 125, no. 7, pp. 709–716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Heit, C. L. Leibson, A. A. Ashrani, T. M. Petterson, K. R. Bailey, and L. J. Melton, “Is diabetes mellitus an independent risk factor for venous thromboembolism? a population-based case-control study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 9, pp. 1399–1405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. D. C. Kress, S. Aronson, M. L. McDonald et al., “Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes,” Annals of Thoracic Surgery, vol. 83, no. 5, pp. 1737–1743, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Sun, P. E. Greilich, S. I. O. Wilson, M. R. Jackson, and C. W. Whitten, “The use of lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia during major vascular surgery,” Anesthesia and Analgesia, vol. 92, no. 2, pp. 344–346, 2001. View at Google Scholar · View at Scopus
  30. M. M. Nanda, M. J. Kauflin, P. G. Jain, and J. C. Yannetta III, “Use of argatroban as a procedural and bridging anticoagulant in a patient undergoing carotid endarterectomy with concomitant atrial fibrillation,” Annals of Pharmacotherapy, vol. 45, no. 3, p. e16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. L.-A. Linkins, A. L. Dans, L. K. Moores et al., “Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, pp. e495–e530, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. C. N. Hess, R. C. Becker, J. H. Alexander, and R. D. Lopes, “Antithrombotic therapy in heparin induced thrombocytopenia: guidelines translated for the clinician,” Journal of Thrombosis and Thrombolysis, vol. 34, no. 4, pp. 552–561, 2012. View at Google Scholar
  33. A. Cuker, “Heparin-induced thrombocytopenia: present and future,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 3, pp. 353–366, 2011. View at Publisher · View at Google Scholar · View at Scopus